CONTACT US

Address
1 Avenue d'Ester - 87280 LIMOGES

Email
info@curlim.eu

Technology behind CLM001

CLM001 is the result of a proprietary three-component nano-formulation, specifically engineered to deliver a curcumin-based active pharmaceutical ingredient (API) with maximum therapeutic potential.

  • Our technology

To overcome this, CLM001 leverages a smart and synergistic delivery platform composed of :

  • A curcumin-based API
    With therapeutic action targeting key drivers of Charcot-Marie-Tooth disease type 1A (CMT1A).
  • Cationic beta-cyclodextrins
    To encapsulate, solubilize, and protect the API, extending its bioavailability.
  • Cellulose nanocrystals (CNCs)
    To act as a carrier, enabling intracellular delivery via a “Trojan Horse” mechanism.
Curlim our technology clm001 2
  • Encapsulation for Protection and Stability

The curcumin-based API is encapsulated in cationic beta-cyclodextrins, a molecule with a hydrophobic cavity that acts as a protective cage.

This encapsulation enhances the API’s solubility, preserves its stability, and extends its bioavailability in the bloodstream.

See Preclinical Results
BIOAVAILABILITY
Measured blood concentration of curcumin (ng/mL) over time.
CLM001 provides sustained release compared to free API
CTL Pure API API-CD/CNCx
  • A Carrier System for Intracellular Delivery

To penetrate cell membranes, the API-cyclodextrin complex is associated with cellulose nanocrystals (CNCs) — biodegradable, hydrophilic crystalline particles derived from cotton fibers.

CNCs act as a “Trojan Horse”, enabling the API to enter the cell via an endocytosis mechanism, and deliver its therapeutic action at the intracellular level.

Confocal microscopy was used to visualize and assess API penetration into cells (PC-3, DU145, HT-29).
Explore the interactive legends below for details

CTL

Untreated control cells (no green fluorescence observed)

Pure API

Poor intracellular penetration of free API (weak green fluorescence)

API-CD/CNCx

Enhanced intracellular delivery of API when encapsulated with CD/CNC complex (strong green fluorescence)

  • A Triple Therapeutic Hit on CMT1A

While research is ongoing, CLM001 has already shown a triple mode of action targeting key mechanisms involved in the progression of Charcot-Marie-Tooth disease type 1A (CMT1A).

Oxidative
stress

In CMT1A, an excess of reactive oxygen species (ROS) damages nerve cells and disrupts mitochondrial function — the cell’s energy system.

CLM001 helps reduce ROS levels and restore mitochondrial membrane potential, protecting nerve cells from further degeneration.

Endoplasmic reticulum (ER) stress

Misfolded proteins in CMT1A cause stress in the endoplasmic reticulum, leading to cellular dysfunction.

CLM001 stimulates protective proteins involved in repair and stress response (such as HSP90, HSC70, and GRP94), helping cells recover and maintain normal function.

Inflammation

Chronic inflammation contributes to nerve damage in CMT1A.

CLM001 has shown the ability to reduce inflammatory markers and increase anti-inflammatory responses (such as MIF), contributing to a healthier nerve environment.